Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...
Pharmacological treatment trends and health care utilization rates were the focus of an observational study of Swedish patients with narcolepsy. Narcolepsy is characterized by symptoms including ...
People with certain types of long-term sleep disorders may use a medicine called sodium oxybate to help treat their condition. This medicine is taken at night and may help people with narcolepsy to ...
Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients. Switching from high-sodium oxybate (SXB) to ...
A new Northwestern Medicine study has demonstrated a new way to treat narcolepsy-related nightmares. The scientists combined cognitive behavioral therapy (CBT) and lucid dreaming to help patients in a ...
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy ...
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results